// App-Quantinova.ai

168 : Myocardial stress perfusion and energetics improves in patients with type 2 diabetes after treatment with a glucagon like peptide-1 receptor agonist (liraglutide)- a randomised, single centre, open label, cross-over drug trial

Researchers

Presenter

  • Amrit Chowdhary

Principal Investigators

  • Nicholas Jex

  • Sindhoora Kotha

  • Marilena Giannoudi

  • Sharmaine Thirunavukarasu

  • Sven Plein

  • Henry Procter

  • Sevval Akkaya

  • Eylem Levelt

  • Peter Kellman

  • John P. Greenwood

Medical Centers

  • University of Leeds, Leeds Institute of Cardiovascular and Metabolic Medicine, Leeds, United Kingdom

  • Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds

  • National Institute of Health, USA

  • University of Leeds

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

  • Genetic Disorder

Disease

  • Type 2 diabetes mellitus

Biomarkers

  • N/A

Drug/Treatment

  • Liraglutide

  • Dobutamine

  • Intranasal glucagon

Outcome

  • N/A

Study Design

  • Randomized

  • Cross Over

  • Open Label

  • Single Center

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved